Oragenics (OGEN) Competitors

Tharimmune (NASDAQ:THAR) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Is THAR or OGEN more profitable?

Tharimmune's return on equity of -489.33% beat Oragenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-489.33%	-264.34%
Oragenics	N/A	-2,087.95%	-486.56%

Does the media favor THAR or OGEN?

In the previous week, Tharimmune and Tharimmune both had 1 articles in the media. Tharimmune's average media sentiment score of 1.89 beat Oragenics' score of 0.00 indicating that Tharimmune is being referred to more favorably in the media.

Company	Overall Sentiment
Tharimmune	Very Positive
Oragenics	Neutral

Which has better earnings and valuation, THAR or OGEN?

Tharimmune is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$7.88	-0.21
Oragenics	N/A	N/A	-$20.66M	-$33.63	-0.04

Do insiders and institutionals have more ownership in THAR or OGEN?

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 10.0% of Tharimmune shares are held by insiders. Comparatively, 4.9% of Oragenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend THAR or OGEN?

Tharimmune currently has a consensus target price of $17.00, suggesting a potential upside of 942.94%. Given Tharimmune's stronger consensus rating and higher possible upside, research analysts clearly believe Tharimmune is more favorable than Oragenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Oragenics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has more volatility and risk, THAR or OGEN?

Tharimmune has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Summary

Tharimmune beats Oragenics on 11 of the 12 factors compared between the two stocks.